S T C Pharmaceutical Import Profile — Saudi Arabia (DGFT 2022–2026)

Name: S T C Pharmaceutical Import Records from India — 2 Products, $5.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

S T C — Pharmaceutical Importer Profile (2026) | 2 Products, $5.0M Trade | TransData Nexus

S T C

Pharmaceutical Importer · Saudi Arabia · Advanced Antibiotics Focus · $5.0M Total Trade · DGFT Verified

S T C is a pharmaceutical importer based in Saudi Arabia with a total trade value of $5.0M across 2 products in 1 therapeutic categories. Based on 132 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. S T C sources from 3 verified Indian suppliers, with Venus Remedies Limited accounting for 96.3% of imports.

S T C — Import Portfolio & Supplier Network

S T C import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to S T C?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Venus Remedies Limited	$5.7M	413	96.3%
Titan Laboratories Private Limited	$149.1K	8	2.5%
Giant International Private Limited	$71.7K

What Formulations Does S T C Import?

Formulation	Value	Ships
Meropenem 1.0 GM powder for solution forinjection or infusion (ronem 1000 MG)	$163.5K	8
Meropenem 1 0 GM powder for solution forinjection or infusion ronem 1000 MG	$157.5K	8
Lastinem 500 MG (imipenem and cilastatin500mg +500MG powder for solution for infustion	$150.0K	3
Ronem 1000 MG (meropenem 1 g powder forsolution for injection or infusion) (moowr scheme vide license no.-03/2023 -ldh	$150.0K	3
Ronem 500 MG (meropenem 500MG powder forsolution for injection or infusion) (moowr scheme vide license no.-03/2023-ldh	$150.0K	3
Ronem 1000 MG(meropenem 1000MG powder for solution for injection or infusion)bn.x4aa034ax4aa044a md.01/2024	$150.0K	3
Ronem (meropenem 1g powder for solutionfor INJ.or infusion)b/no. x4ca184a, x4ba034d,m/dt.03/24,02/24,e/dt.02/26	$150.0K	3
Ronem (meropenem 1GM powder for solutionfor INJ.or infusion)b/no.x4ca194b,m/dt.03/2024, exp. dt.	$150.0K	3
Meropenem 1.0 GM powder for solution forinjection or infusion ronem 1000MG	$100.0K	2
Ronem 1.0 GM meropenem 1000MG powder for solution for injection or infusion Each vial contains: active	$100.0K	2
Cefuroxime for injection750mg(Each vialcontains cefuroxime sodium equivalent tocefuroxime750mg)cefuroxime-venus 750MG	$93.5K	3
Enoxaparin sodium injection BP (60MG/0.6ML)coguperin 60 MG	$82.5K	3
Enoxaparin sodium injection BP(60MG/0.6ML)coguperin 60MG,m/d.x4ba073a,x4ba083a,x4ca113b,m/t.02/24,03/24,e/dt.01/27	$82.1K	3
Ronem 1000 MG (meropenem 1000MG powder for solution for injection or infusion)batch no.	$79.6K	3
Enoxaparin sodium injection BP(80MG/0.8ML)coguperin 80MG,b/n.x4ba094a,x4ba104a,x4ba104c,m/d.02/24	$76.9K	3

S T C imports 342 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meropenem	Advanced Antibiotics	$4.4M	95	2.0%	7
2	Imipenem	Advanced Antibiotics	$589.0K	37	1.8%	12

S T C imports 2 pharmaceutical products across 1 categories into Saudi Arabia totaling $5.0M.

S T C — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

S T C is a pharmaceutical importer based in Saudi Arabia, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Saudi pharmaceutical distribution network, ensuring the availability of essential medications within the Kingdom. While specific details about its headquarters and parent company are not publicly disclosed, S T C's operations are integral to the healthcare supply chain in Saudi Arabia.

2Distribution Network

S T C's distribution network encompasses multiple warehouse locations strategically situated across Saudi Arabia to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of imported medications. Geographically, S T C's coverage spans the entire Kingdom, ensuring that both urban and rural areas have access to necessary pharmaceutical supplies.

3Industry Role

Within Saudi Arabia's pharmaceutical supply chain, S T C functions primarily as a wholesaler and distributor. By importing finished pharmaceutical formulations from international suppliers, the company bridges the gap between manufacturers and end-users, including hospitals, clinics, and pharmacies. This role is crucial in maintaining a steady supply of essential medications throughout the Kingdom.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — S T C

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

S T C's sourcing strategy exhibits a high degree of concentration, with 96.3% of its imports from India supplied by Venus Remedies Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the substantial volume of shipments (413) suggests a stable and long-term relationship, potentially mitigating some of these risks. The remaining 3.7% of imports are sourced from Titan Laboratories Private Limited and Giant International Private Limited, indicating a limited diversification in supplier base.

2Supply Chain Resilience

The resilience of S T C's Indian supply chain is contingent upon the reliability of its primary supplier, Venus Remedies Limited. The company's extensive portfolio of 342 unique formulations imported from India suggests a diversified product range, which can help mitigate risks associated with single-source dependency. However, the lack of backup suppliers for key products may expose S T C to vulnerabilities in the event of supply chain disruptions. Additionally, the company's exposure to shipping routes and potential regulatory changes in India could impact the stability of its supply chain.

3Strategic Implications

Importing Pharmaceuticals into Saudi Arabia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Saudi Arabia

1Regulatory Authority & Framework

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body overseeing pharmaceutical imports into Saudi Arabia. Key legislation governing pharma imports includes the Implementing Regulations of the Law of Combating Narcotics and Psychotropic Substances, which outlines procedures for importing controlled substances. The marketing authorization pathway for Indian generics involves obtaining prior approval from the SFDA, ensuring that imported products meet the Kingdom's safety, efficacy, and quality standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Saudi Arabia stipulate that importers must obtain prior approval from the SFDA before bringing products into the Kingdom. Recognized Good Manufacturing Practice (GMP) certificates, such as EU GMP, WHO GMP, or PIC/S, are mandatory to ensure product quality and safety. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Saudi Arabia.

3Quality & Labeling

S T C — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

S T C's focus on importing advanced antibiotics, specifically meropenem and imipenem, aligns with the growing demand for effective treatments against resistant bacterial infections in Saudi Arabia. The market demand for these products is driven by the increasing prevalence of multi-drug-resistant pathogens and the need for potent antibiotics in hospital settings. By concentrating on this therapeutic area, S T C addresses a critical need within the Kingdom's healthcare system.

2Sourcing Profile

S T C's sourcing strategy is centered on generic drugs, primarily importing finished formulations from India. The company's preference for generic formulations allows for cost-effective procurement while maintaining access to essential medications. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for S T C's procurement needs.

3Market Positioning

Based on its product mix, S T C serves the hospital and wholesale distribution segments of the Saudi Arabian market. The company's focus on advanced antibiotics positions it as a key supplier to healthcare institutions requiring specialized medications for treating severe infections. Additionally, S T C's role in wholesale distribution ensures that these critical products are accessible to a broader range of healthcare providers across the Kingdom.

Seller's Guide — How to Become a Supplier to S T C

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with S T C by offering competitive pricing, reliable delivery schedules, and compliance with Saudi Arabian regulatory standards. Gaps in S T C's current sourcing include a limited diversification of suppliers, which presents an opportunity for new entrants to provide alternative sources for the products currently imported from Venus Remedies Limited. By addressing these gaps, new suppliers can establish a foothold in the Saudi Arabian pharmaceutical market.

2Requirements & Qualifications

Indian exporters seeking to supply S T C and the Saudi Arabian market must obtain prior approval from the SFDA, ensuring that their products meet the Kingdom's safety, efficacy, and quality standards. Possessing recognized GMP certificates, such as EU GMP, WHO GMP, or PIC/S, is mandatory. Additionally, compliance with Saudi Arabian labeling requirements, including bilingual labeling in Arabic and English, and adherence to serialization mandates are essential.

3How to Approach

Frequently Asked Questions — S T C

What products does S T C import from India?

S T C imports 2 pharmaceutical products across 1 categories. Top imports: Meropenem ($4.4M), Imipenem ($589.0K).

Who supplies pharmaceuticals to S T C from India?

S T C sources from 3 verified Indian suppliers. The primary supplier is Venus Remedies Limited (96.3% of imports, $5.7M).

What is S T C's total pharmaceutical import value?

S T C's total pharmaceutical import value from India is $5.0M, based on 132 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does S T C focus on?

S T C imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full S T C Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.